

### **Amendments to the Claims**

Please replace the previously pending claims with the following claim listing.

1-22. (Canceled)

23. (Currently amended) A pharmaceutical composition which dissociates a protein complex comprising an insulin-like growth factor (IGF) and an insulin-like growth factor binding protein-2 (IGFBP-2), wherein the composition has a greater affinity for IGFBP-2 than for IGFBP-1, IGFBP-3, IGFBP-4, IGFBP-5, and IGFBP-6.

24. (Currently amended) The composition of claim 23, wherein the protein complex is further defined as a dimeric complex comprising IGF and IGFBP-2.

25. (Currently amended) The composition of claim 24, wherein the protein complex further comprises an acid labile subunit (ALS), wherein the ratio of IGF to IGFBP-2 to ALS is 1:1:1.

26. (Original) The composition of claim 24, wherein the composition is a small molecule.

27. (Original) The composition of claim 24, wherein the composition is a peptide.

28-31. (Cancelled)

32. (New) A pharmaceutical composition which dissociates a protein complex comprising an insulin-like growth factor (IGF) and an insulin-like growth factor binding protein (IGFBP), wherein the composition is a small molecule.

33. (New) The composition of claim 32, wherein the protein complex is further defined as a dimeric complex comprising IGF and IGFBP.

34. (New) The composition of claim 32, wherein the protein complex further comprises an acid labile subunit (ALS), wherein the ration of IGF to IGFBP to ALS is 1:1:1.